Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Ibuprofen Arginine→

Ibuprofen Arginine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
57469-82-6
Molecular formula
C19H32N4O4
Molecular weight
380.5 g/mol
Drug class
Non-steroidal anti-inflammatory drug (NSAID)propionic-acid derivative
Mechanism of action
Reversibly inhibits cyclo-oxygenase-1 and cyclo-oxygenase-2, reducing prostaglandin synthesis and producing analgesic, antipyretic and anti-inflammatory effects. Arginine and lysine are counter-ions in particular salt formulations and do not create a different ibuprofen pharmacological target.
Indications / reported uses
  • Symptomatic relief of mild-to-moderate pain and fever
  • Treatment of inflammatory and painful conditions including osteoarthritis, rheumatoid arthritis, dysmenorrhoea and musculoskeletal pain
  • Paediatric fever and pain relief with age- and formulation-appropriate products; product-specific indications and dose limits apply

Sources: US DailyMed — Ibuprofen products · NHS — Ibuprofen for adults

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Ibuprofen Arginine Environmental Risk Assessment (ERA) (the Ibuprofen Arginine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.